SUMMARY Electrophysiological effects of 2 to 2-5 mg/kg iv disopyramide were studied in 10 patients with dual nodal pathways who used a slow pathway for anterograde and a fast pathway for retrograde conduction during paroxysmal supraventricular tachycardia (mean cycle length 3085 + 37 ms; range 260-370 ms). Disopyramide terminated the tachycardia in six cases by production of ventriculoatrial block in five and by sinus overdrive in one. In the remaining four patients cycle length of the paroxysmal supraventricular tachycardia increased significantly from 270+ 8 ms to 377*5+28 ms. In all 10 patients disopyramide depressed retrograde fast pathway conduction manifest by an increase in mean ventricular paced cycle length producing ventriculoatrial block from -296*5+25 ms to 358+ 60 ms, and increase in retrograde fast pathway effective refractory period from t<246+ 34 ms to 325±36 ms; the drug abolished ventriculoatrial conduction in two cases.
respectively) suggesting that anterograde conduction was not crucial either for sustainment or for failure to initiate paroxysmal supraventricular tachycardia after the drug.
Paroxysmal supraventricular tachycardia could not be reinduced in six cases after disopyramide. In the other four the ventricular paced cycle lengths producing ventriculoatrial block (318+41 ms) and effective refractory period of retrograde fast pathway (320±+28 ms) were shorter than the cycle length of reinduced paroxysmal supraventricular tachycardia (367.5 + 35 ms) allowing perpetuation of the tachycardia.
We conclude that disopyramide breaks atrioventricular nodal re-entrant tachycardia by specific blockade of the retrograde fast pathway though the effect on anterograde atrioventricular nodal conduction is variable.
Electrophysiological studies have shown that longitudinal dissociation of the antrioventricular node into dual pathways constitutes the most common mechanism of re-entry in the mediation of paroxysmal supraventricular tachycardia.12 Usually the tachycardia uses the slow pathway for anterograde conduction and the fast pathway for the return impulse; and the three most commonly recommended drugs, that is verapamil, digitalis, and propranolol, inhibit the arrhythmia by depression of conduction through the Accepted for publication 10 February 1983 anterograde slow pathway.3-5 Some studies have also reported the effects of procainamide6 and quinidine7 8 on laboratory induction of paroxysmal supraventricular tachycardia.
Disopyramide phosphate, a synthetic compounc with antiarrhythmic actions similar to those of quinidine, was introduced by Mokler and Van Arman9 in 1962. Because of its demonstrably variable effects on the atrioventricular nodal conduction and refractory periods it was not construed to be effective in paroxysmal supraventricular tachycardia mediated by dissociation of the atrioventricular node into dual 532 Disopyramtde in paroxysmal supraventricular tachycardia pathways.'I01 On the other hand, in patients with paroxysmal supraventricular tachycardia associated with Wolff-Parkinson-White syndrome, disopyramide inhibits both anterograde and retrograde conduction through the bypass tract'0 12 and has been recommended for use in paroxysmal supraventricular tachycardia using atrioventricular node bypass tract. A few studies conducted in a small cohort of patients without overt pre-excitation have shown that intravenous disopyramide terminates 33 to 68% of acute attacks of paroxysmal supraventricular tachycardia. intracardiac electrophysiological studies to delineate the mechanism of paroxysmal supraventricular tachycardia or its mode of termination were, however, performed in any of these investigations. It is well recognised that concealed atrioventricular accessory pathways, functionally silent during sinus rhythm and therefore clinically unsuspected, participate in 15 to 30% cases of re-entrant paroxysmal supraventricular tachycardia'7; hence it becomes obligatory to rule out participation of this circuit in evaluating the effect of drugs on atrioventricular nodal re-entrant paroxysmal supraventricular tachycardia. The efficacy of intravenous disopyramide in terminating episodes of paroxysmal supraventricular tachycardia in a select group of patients with dual atrioventricular nodal pathway mediation has thus far not been adequately investigated, and formed the aim of the present study.
Subjects and methods
Ten patients, four men and six women, aged 25 to 56 years (mean 42.8 years) comprised the study material selected on the following criteria: (1) a history of electrocardiographic documented recurrent paroxysmal supraventricular tachycardia, (2) absence of preexcitation during sinus rhythm in all available electrocardiograms, (3) electrophysiological documentation of longitudinal dissociation of the atrioventricular node during paroxysmal supraventricular tachycardia, and (4) exclusion of a retrogradely active concealed bypass tract during paroxysmal supraventricular tachycardia by intracardiac catheter techniques.
Electrophysiological studies were performed in the post-absorptive non-sedated state a week after discontinuation of all cardioactive medications. Informed written consent was obtained from all. One patient had angina of effort; others were free of organic heart disease.
Six 6F bipolar catheters were introduced transvenously and positioned at high, mid, and low right atrium, coronary sinus, tricuspid valve (for His bundle electrogram), and right ventricular apex. The mid-right atrial and right ventricular electrodes were used for pacing and programmed stimulation. The 533 electrograms from the high and low right atrium, tricuspid valve, and coronary sinus were recorded (frequency range 30 to 500 Hz) together with multiple scalar leads (combinations of lead I, II, III, aVF, or VI) on VR-12 photographic recorder (Electronics for Medicine) or on Mingograf 8 channel ink jet recorder (Siemens-Elema) at paper speeds of 100 and 250 mm/s. Intracardiac stimulation was performed at approximately twice the diastolic threshold by a battery powered stimulator (Digitimer arrhythmia investigating system, Neurolog-4279) producing square wave pulses of 2 ms duration.
The study consisted of evaluation of anterograde and retrograde conduction properties, refractory periods of the slow and fast pathways, and the mechanism of paroxysmal supraventricular tachycardia, pursued in the following sequence: (a) incremental atrial pacing to a paced cycle length producing atrioventricular block; (b) programmed atrial extrastimulus testing at decreasing coupling intervals using single (AlA2) extrastimuli during sinus rhythm and during one or more atrial paced cycle lengths. showing failure of programmed ventricular extrastimulation to pre-excite the atrium when delivered at the critical time when the His bundle was rendered refractory by anterograde depolarisation during the normal course of paroxysmal supraventricular tachycardia. Patients with concealed bypass tract participation during the tachycardia2 were excluded from the study.
Results
The results are set out in the Table. The mean basal cycle length during sinus rhythm was 578±+107 ms (range 440 to 740 ms); the mean AH interval was 78*8+13 ms (range 60 to 90 ms) and the mean HV time was 44+6 ms (range 35 to 50 ms).
INDUCTION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Sustained paroxysmal supraventricular tachycardia could be induced in all 10 patients: by rapid atrial pacing in seven, by single atrial extrastimulus in three, by double atrial extrastimulus in two, and by rapid ventricular pacing in one case. Induction of paroxysmal supraventricular tachycardia by atrial stimulation was related to achievement of a critical AH prolongation consequent to anterograde block of the fast pathway and the resultant atrioventricular conduction via the slow pathway. Induction of paroxysmal supraventricular tachycardia by ventricular pacing was obtained without a ventriculoatrial delay, reflecting block in the retrograde slow pathway.
Cycle length of the tachycardia ranged between 260 and 370 ms (mean 308.5+37 ms). All patients showed anterograde conduction through the slow pathway and retrograde conduction through the fast pathway. (Fig. 3) . The control study.
The effective refractory period of the anterograde fast pathway was -274±56 ms (range <200 to 400 ms) before, and -284±44 ms (range <220 to 360 ms) after the drug (NS) (Fig. 4) . The effective refractory period of the anterograde slow pathway could not be compared before and after disopyramide because atrioventricular nodal conduction was limited by atrial refractoriness before and/or after the drug.
RETROGRADE CONDUCTION PROPERTIES
Disopyramide increased the effective refractory period of the ventricle from 215±12 ms (range 200 to 230 ms) to 229± 11 ms (range 210 to 240 ms) (p<0-05). During the control study the ventricular paced cycle length that produced ventriculoatrial block ranged from <260 to 325 ms (mean -296-5±25 ms). After disopyramide the ventricular paced cycle length that produced ventriculoatrial block increased in all the patients irrespective of whether or not the paroxysmal supraventricular tachycardia was terminated by the drug (mean 358± 60 ms; range 286 to 470 ms) (p<0.01) (Fig. 5) . In two cases (1 and 4) ventricular pacing at a cycle length just shorter than the sinus cycle length disclosed complete abolition of ventriculoatrial conduction (Fig. 6) . The ventriculoatrial conduction times at identical pacing rates were longer after disopyramide compared with control in all the cases. In all the subjects the cycle length of paroxysmal supraventricular tachycardia (308-5±37 ms) was longer than the cycle length that produced ven- triculoatrial block before disopyramide (296-5+25 ms).
The effective refractory period of the retrograde fast pathway before disopyramide was -246± 34 ms (range <210 to 300 ms). After In all patients, the cycle length of paroxysmal supraventricular tachycardia (308.5-± 37 ins) was longer than the ventricular paced cycle length producing ventriculoatrial block (-,296-5±+25 ins) before disopyranmide. In those six patients in whom paroxysmal supraventricular tachycardia could not be induced after the drug the ventricular paced cycle length that produced ventriculoatrial block after disopyramide (385+53 ms) was longer than the cycle length of paroxysmal supraventricular tachycardia (321±+-33 ms) during control study. In the other four patients with inducible paroxysmal supraventricular tachycardia after the drug the cycle lengths producing ventriculoatrial block (318±41 ms) and effective refractory period of the retrograde fast pathway (320±_28 ms) were shorter than the post-drug cycle lengths of paroxysmal supraventricular tachycardia (367.5±35 ms), indicating that the fast pathway was not sufficiently inhibited to prevent perpetuation of paroxysmal supraventricular tachycardia.
Discussion
The and overall efficacy of the drug in relation to conventional and other newer antiarrhythmic drugs in a select group of patients mediating the tachycardia via dual atrioventricular nodal pathways have not so far been studied in detail. Disopyramide could convert 60% of such attacks of paroxysmal supraventricular tachycardia into normal sinus rhythm in our study material. Swiryn et al.26 reported that oral disopyramide could prevent induction of sustained paroxysmal supraventricular tachycardia in six out of nine cases (67%) of atrioventricular nodal re-entrance. Intravenous verapamil converts 80 to 1000/o of episodes of paroxysmal supraventricular tachycardia into sinus rhythm but is much less effective in preventing recurrences when administered orally32728 because of considerable first pass hepatic metabolism. Other drugs that have been shown to be effective in preventing induction of atrioventricular nodal reentrant paroxysmal supraventricular tachycardia include (percentages in parentheses): intravenous ouabain (44 to 54%),4 7 intravenous propranolol (41 to 44%),5 7 intravenous ouabain plus propranolol (58%),7 intravenous procainamide (65%),6 and oral quinidine (78%).78 It appears from this review of published reports that, though somewhat less effective than verapamil in converting acute attacks, intravenous disopyramide compares favourably with other drugs in controlling paroxysmal supraventricular tachycardia mediated by dual atrioventricular nodal pathways and may possess the additional advantage of effectively preventing recurrences on chronic oral treatment. 26 We have not attempted specifically to test in our study whether chronic oral administration of disopyramide prevents recurrence of paroxysmal supraventricular tachycardia, but such proof in a large number of patients with dissociation of the atrioventricular node into dual pathways and paroxysmal supraventricular tachycardia is desirable.
As observed in our study, Befeler et al. 29 have also reported no change or shortening of the atrial effective and functional refractory periods after intravenous administration of disopyramide. On the other hand, other investigators' 030 31 found increases in these variables. An increase in ventricular effective refractory period has also been shown,'0 but anterograde atrioventricular conduction has been shown to be depressed, unaffected, or even facilitated by the drug.'0 293032 Both anterograde slow pathway conduction (atrial paced cycle length producing atrioventricular block) and effective refractory period of anterograde fast pathway were not significantly affected in the present study.
In sharp contrast to its effect on the anterograde conduction through the atrioventricular node, disopyramide selectively and uniformly depressed conduction through the retrograde fast pathway in all the 541 patients, as shown by the lowering of ventricular paced rate producing ventriculoatrial block, and an increase in the effective refractory period of the retrograde fast pathway. This effect was responsible for termination of paroxysmal supraventricular tachycardia in five patients (ventriculoatrial block) and prevention of reinduction of paroxysmal supraventricular tachycardia in six cases as shown by failure to induce atrioventricular nodal re-entrant echo despite achievement of an AH interval equivalent to or longer than the one that precipitated paroxysmal supraventricular tachycardia in the control state. It is clear from our data that the fast pathway, while unaffected in the anterograde direction, was rendered incapable of conducting retrogradely. Though the nature of this retrograde pathway is subject to some discussion, the available evidence indicates that it is located intranodally and is identical to the anterograde fast pathway. 33 The results of other studies on the effect of oral quinidine,78 and oral disopyramide26 on induction of atrioventricular nodal re-entrant tachycardia corroborate the data obtained by us on intravenous disopyramide on electrophysiologically confirmed dissociation of atrioventricular nodal pathways mediated paroxysmal supraventricular tachycardia. In our study disopyramide did marginally depress the anterograde slow pathway conduction in some patients but this did not appear to be a limiting factor in inducing or sustaining the tachycardia. This is in contradistinction to the actions of intravenous verapamil,3 27 28 digitalis,47 and propranolol57 which, by and large, increase the anterograde slow pathway refractoriness and only occasionally depress the retrograde fast pathway conduction. Intravenous procainamide prevents induction of paroxysmal supraventricular tachycardia in some patients6 by inhibiting the retrograde fast pathway but may have the disadvantage of decreasing the anterograde slow pathway refractoriness (vagolytic effect) in some patients. Atrioventricular conduction was facilitated by intravenous disopyramide in one of our patients (case 5) who overdrove the paroxysmal supraventricular tachycardia by sinus tachycardia. Alterations in the sinus rate after disopyramide therapy are variable and related to a complex interaction between the direct depressant action on sinus node automaticity,32 its anticholinergic effects,34 and reflex baroreceptor mediated sympathomimetic effect caused by peripheral vasodilatation. Anterograde conduction was significantly depressed by oral disopyramide in the study of Swiryn et al. 26 The discrepancy between their data and our results could possibly be the result of more prominent anticholinergic effects of the drug after intravenous administration.
Whenever disopyramide failed to terminate paroxgroup.bmj.com on June 26, 2017 -Published by http://heart.bmj.com/ Downloaded from ysmal supraventricular tachycardia, it produced a reduction in tachycardia rate. In those four patients in whom paroxysmal supraventricular tachycardia was still inducible after disopyramide, the depression in retrograde conduction was insufficient to prevent continuation of the tachycardia. Anterograde conduction was depressed in three and facilitated in one of these cases. The cycle length of the reinduced paroxysmal supraventricular tachycardia was, however, significantly increased in all the patients.
Our data indicate that intravenous disopyramide depresses retrograde fast pathway conduction and thus terminates, or prevents induction of, paroxysmal supraventricular tachycardia in patients with atrioventricular nodal re-entrant tachycardia. Care needs to be exercised in prescribing the drug routinely in all non-specific supraventricular tachycardias because of the possibility of an increase in ventricular rate by development of 1:1 conduction through the atrioventricular node in cases of atrial flutter or paroxysmal supraventricular tachycardia caused by an ectopic atrial focus or intra-atrial re-entry in the absence of concomitant administration of atrioventricular nodal depressants (digoxin, beta blockers). This risk of 1:1 conduction on the development of atrial flutter in patients receiving disopyramide for long term prophylaxis against paroxysmal supraventricular tachycardia can be assessed during intracardiac electrophysiological study. It could not be assessed in the absence of such a test were the drug to be given empirically to all patients with intranodal paroxysmal supraventricular tachycardia because the infra-Hisian delay induced by the drug may or may not protect the ventricles from rapid response. 
